Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

NCT04406571 | Completed

• 1 other identifier: PO20042
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%. Since December 2019, a new coronavirus (Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2) is responsible of COVID-19 infection with potentially severe respiratory syndrome or even multi-organ failure. An increased risk of severe COVID-19 infection in cancer patients is suggested in several Chinese series. Cancer care structures quickly reorganized to limit high-risk situations (diagnostic procedure, major surgery, cytotoxic poly-chemotherapy) and use alternatives such as on-hold chemotherapy. These reorganizations could be associated with a loss of chance for pancreatic adenocarcinoma.

Conditions

Pancreatic Adenocarcinoma

Keywords

pancreatic adenocarcinoma; patient management; healthcare system reorganization; SARS-CoV-2

Outcome Measures

Primary Outcomes (1)

• Pancreatic adenocarcinoma treatment

  curative surgery (with or without chemotherapy), chemotherapy only or exclusive supportive care

  6 months

Study Arms (2)

"pancreatic adenocarcinoma before COVID-19 containment " group

patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 16/03/2020.

Other: Data record

"pancreatic adenocarcinoma after COVID-19 containment " group

patients with pancreatic adenocarcinoma assessed during multidisciplinary meeting in one participating center between 17/03/2020 and 31/10/2020.

Other: Data record

Interventions

Data record OTHER

Data record

"pancreatic adenocarcinoma after COVID-19 containment " group; "pancreatic adenocarcinoma before COVID-19 containment " group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with pancreatic adenocarcinoma diagnosed between 01/09/2019 and 31/10/2020.

You may qualify if:

• aged 18 or over,
• with pancreatic adenocarcinoma diagnosed by anatomopathological specimen or without biopsy but with suspicion of pancreatic adenocarcinoma in presence of imaging techniques or Ca19.9 level without evidence for neuroendocrine tumor,
• assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 31/10/2020,
• accepting to participate to the study,
• with or without SARS-CoV-2 infection.

You may not qualify if:

• with neuroendocrine neoplasia
• for whom histology showed non pancreatic
• with cystadenoma or IPMN without invasive adenocarcinoma

Sponsors & Collaborators

• CHU de Reims: lead

Study Sites (1)

Damien JOLLY

Reims, France

Location

Related Publications (1)

• Brugel M, Letrillart L, Evrard C, Thierry A, Tougeron D, El Amrani M, Piessen G, Truant S, Turpin A, d'Engremont C, Roth G, Hautefeuille V, Regimbeau JM, Williet N, Schwarz L, Di Fiore F, Borg C, Doussot A, Lambert A, Moulin V, Trelohan H, Bolliet M, Topolscki A, Ayav A, Lopez A, Botsen D, Piardi T, Carlier C, Bouche O. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID). Eur J Cancer. 2022 May;166:8-20. doi: 10.1016/j.ejca.2022.01.040. Epub 2022 Feb 10.

  PMID: 35259629 DERIVED

MeSH Terms

Interventions

Electronic Health Records

Intervention Hierarchy (Ancestors)

Medical Records Systems, Computerized; Medical Records; Records; Data Collection; Epidemiologic Methods; Investigative Techniques; Organization and Administration; Health Services Administration; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2020
• First Posted: May 28, 2020
• Study Start: April 1, 2020
• Primary Completion: December 31, 2021
• Study Completion: May 31, 2022
• Last Updated: January 24, 2024

Record last verified: 2024-01

Locations

FR (1)